Pharma Analytics in India: MR Performance, Territory, and Compliance

India is the pharmacy of the world — the largest producer of generic medicines, supplying 20% of global generic drug exports. The domestic pharma market is projected to reach $130 billion by 2030. Analytics is critical for Indian pharma companies navigating intense competition, complex distribution, and evolving regulatory requirements.

Why Pharma Analytics Matters in India

Indian pharma has distinct analytics needs:

• Doctor-driven demand: Unlike consumer goods, pharma demand is driven by physician prescriptions — tracking doctor engagement and prescription behaviour is central
• Large field forces: Top Indian pharma companies deploy 5,000–15,000+ MRs, making field force productivity a critical analytics domain
• Multi-tier distribution: Company → C&F → super-stockist → stockist → retail chemist — each tier requires analytics
• Regulatory intensity: DCGI, CDSCO, Drug Price Control Order (DPCO), and state drug licensing create compliance data requirements
• Intense competition: 3,000+ pharma companies in India mean every territory and doctor relationship matters

Core Pharma Metrics for Indian Companies

MR Productivity Metrics

• Doctor coverage: Number of doctors visited per day/month vs target
• Call frequency: How often each doctor is visited (A-class doctors: weekly, B-class: fortnightly, C-class: monthly)
• Calls per day: Average field calls completed — Indian benchmark is 8–12 calls per day
• New doctor additions: MRs are expected to expand the prescriber base continuously
• Input cost per call: Travel, samples, and promotional material cost per doctor visit
• Sales per MR: Revenue generated per MR per month — the headline productivity metric

Territory and Sales Metrics

• Territory-wise primary and secondary sales: Tracked by division, region, and headquarters
• RCPA (Retail Chemist Prescription Audit): Estimates prescription share by tracking actual retail sales at chemist level
• New product contribution: Revenue from products launched in the last 12–24 months
• Therapy-wise growth: Performance by therapeutic segment (cardiology, diabetology, antibiotics, etc.)
• Market share by territory: Using IQVIA/AIOCD data benchmarked against company sales

Stockist and Distribution Metrics

• Stockist ROI: Margin earned by the stockist after all costs
• Stock days at stockist: Target is 21–30 days for most products
• Stockist claim settlement time: Speed of processing claims for expired stock, damage, and rate differences
• Fill rate: Percentage of retailer orders fulfilled by stockist
• Outstanding days: Average receivable days from stockist to company

Compliance and Regulatory Metrics

• DPCO compliance: Products under price control tracked against ceiling prices
• Batch-wise expiry tracking: Ensuring near-expiry stock is identified and managed
• Adverse event reporting: Pharmacovigilance data tracking
• Sample distribution compliance: Samples given vs policy limits per doctor
• License renewal tracking: Drug license validity across stockists and C&F agents

Pharma Analytics Dashboards

National Sales Manager Dashboard

• All-India sales: primary and secondary, MTD and YTD vs target
• Division-wise performance ranking
• Top 20 products by revenue and growth
• New product launch tracker (month-by-month ramp-up vs plan)
• MR headcount and vacancy status

Regional Business Manager Dashboard

• Headquarters-wise sales and MR productivity
• Doctor coverage and call compliance
• Stockist-wise billing and outstanding
• Competitor activity tracker (new launches, scheme alerts from field)
• RCPA analysis for key brands

Brand Manager Dashboard

• Brand-wise sales trend and market share
• Therapy area growth vs market growth
• Doctor prescriber pyramid (number of doctors prescribing at different volume tiers)
• Promotional spend vs sales correlation
• Regional performance variation for the brand

Compliance Dashboard

• DPCO product list with price compliance status
• Batch-wise stock tracking with expiry alerts
• Sample distribution audit
• Regulatory submission tracker (DCGI filings, stability data)
• Pharmacovigilance case status

Data Sources in Indian Pharma

• SFA/CRM: Medismart, Phlexglobal, Veeva CRM (for MNCs), or custom-built SFA apps — capture MR activity and doctor interactions
• ERP: SAP (large companies), Tally (mid-size), custom ERP solutions
• DMS: Stockist billing data captured through distributor software
• Syndicated data: IQVIA (formerly IMS Health) and AIOCD-AWACS — industry-standard prescription and market data
• Regulatory portals: CDSCO Sugam portal for drug approvals, DPCO ceiling price databases

Key Challenges in Indian Pharma Analytics

Data Quality from Field Force

MR-reported data (doctor visits, RCPA inputs) can be unreliable. Progressive companies use geo-tagged visit confirmation, automated RCPA through retail audits, and exception-based review to improve data quality.

Prescription Attribution

Linking a doctor's prescription to actual sales at the chemist level is pharma's hardest analytics problem. RCPA audits provide estimates but not complete visibility.

Fragmented Distribution Data

Secondary sales data from thousands of stockists across India is often delayed, incomplete, or inconsistent. Companies investing in DMS connectivity and incentivising stockist compliance get better analytics.

Balancing Growth with DPCO Compliance

With the National List of Essential Medicines expanding, more products fall under price control. Analytics must track both revenue growth and price compliance simultaneously.

See BI for pharma India for tool comparison, and sales dashboard for general sales analytics guidance.